

[advances.sciencemag.org/cgi/content/full/6/32/eaba0995/DC1](https://advances.sciencemag.org/cgi/content/full/6/32/eaba0995/DC1)

## Supplementary Materials for

### **Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and $T_H17$ responses**

Youhui Si, Qiaomu Tian, Fan Zhao, Sean H. Kelly, Lucas S. Shores, Daniel F. Camacho, Anne I. Sperling, Michael S. Andrade, Joel H. Collier\*, Anita S. Chong\*


\*Corresponding author. Email: [achong@uchicago.edu](mailto:achong@uchicago.edu) (A.S.C.); [joel.collier@duke.edu](mailto:joel.collier@duke.edu) (J.H.C.)

Published 7 August 2020, *Sci. Adv.* **6**, eaba0995 (2020)  
DOI: 10.1126/sciadv.aba0995


#### **This PDF file includes:**

Figs. S1 to S8

# Supplementary materials



**Fig. S1. Flow cytometry discrimination of lung cell populations. (A) Gating strategy for the identification lung DC and DC subsets. (B) FMO controls.**



**Fig. S2. Eα presentation by DCs in lung, mediastinal (MLN) or cervical (CLN) lymph nodes on day 4 after EαQ11 I.N. immunization.** C57BL/6 mice were intranasally immunized with EαQ11. Lung, MLN and CLN were collected on day 4 post-immunization. **(A)** Representative flow cytometry plots displaying pEα:I-A<sup>b</sup>-positive CD11b<sup>+</sup> or CD103<sup>+</sup> DCs in the lung, MLN and CLN. **(B)** Percentage of Eα:I-A<sup>b</sup>-positive CD11b<sup>+</sup> or CD103<sup>+</sup> DCs in the lung, MLN and CLN. Each dot represents 1 mouse. Data are mean ± SEM from 2 independent experiments. \*\*\**p* < 0.001, \*\**p* < 0.01, \**p* < 0.05 by two-way ANOVA.







Fig. S3. Gating strategy for the identification PKH26<sup>+</sup> DC subsets in lung.



**Fig. S4. Gating strategy for identifying Th1, Th2, Th17, Tregs, IL-17A or IFN $\gamma$  producing ROR $\gamma$ t<sup>+</sup> cells in the lung.**



**Fig. S5. Egress of lymphocyte from secondary lymphoid organs is blocked after FTY720 treatment. (A)** Percentages of CD4<sup>+</sup> T cells in the blood at 4 days after FTY720 treatment. **(B)** Representative flow cytometry plots displaying low CD44 expression by naïve TEa cells used in adoptive transfer, compared to EαQ11-immunized B/6 T cells. **(C)** The number of TEa T cells 5 days after adoptive transfer of 10,000 TEa T cells, immunization and FTY720 treatment. Data shown are means  $\pm$  SEM from  $\geq 2$  independent experiments. \*\*\*\* $p < 0.0001$ , \*\* $p < 0.01$  by unpaired, two-tailed t-test **(A, C)**.



**Fig. S6. Expression of Ki-67 by TEa T cells in the lung and draining LN.** (A) Representative flow cytometry plots displaying Ki-67 expression by TEa T cells from the MLN (top) and lung (bottom), 5 days after adoptive transfer of 10,000 TEa T cells, immunization and FTY720 treatment. Data are presented as (B) MFI of Ki-67 expression or (C) percentage of Ki-67 positive of TEa T cells in the MLN and lung. Each dot represents 1 mouse. Data shown are means  $\pm$  SEM from  $\geq 2$  independent experiments by unpaired, two-tailed t-test (B, C).





Fig. S7. Representative flow cytometry plots of the expression of CD44, CD62L, CD11a, CD69 and CD103 by lung TEa T cells.



**Fig. S8. Phenotype of expanded TEa T cell in lung and MLN on day 3 and 5 after adoptive transfer of 50,000 TEa T cells and EαQ11 I.N. immunization. (A)** Percentage of CD11a<sup>+</sup> TEa T cells in the lung and MLN. **(B)** Percentage of CD69<sup>+</sup> TEa T cells in the lung and MLN. **(C)** Percentage of CD103<sup>+</sup> TEa T cells in the lung and MLN. **(D)** The total numbers of CD11a<sup>+</sup> TEa T cells in the lung and MLN. **(E)** The total numbers of CD69<sup>+</sup> TEa T cells in the lung and MLN. **(F)** The total numbers of CD103<sup>+</sup> TEa T cells in the lung and MLN. Each dot represents 1 mouse. Data shown are means ± SEM from ≥2 independent experiments. \*\*\*\**p* < 0.0001, \*\*\**p* < 0.001, \*\**p* < 0.01, \**p* < 0.05 by two-way ANOVA (A-F).